GenoGenix

GenoGenix, LLC is a Florida-based pharmaceutical and healthcare business associated with a 503B outsourcing facility in Boca Raton. The company serves healthcare professionals and medical practices through a provider-oriented business model involving pharmaceutical products, online ordering, and specialized healthcare supply.

Its commercial activities include products such as injectable preparations and other pharmaceutical formulations, as reflected in its online catalog and FDA inspection records. The company also maintains educational resources covering selected compounds and product-related research. Its website describes an interest in research and development and specialized delivery approaches, including initiatives involving peptide-based products.

GenoGenix’s customer base includes medical offices, clinics, and qualified healthcare customers. Its online store provides product listings and requires customers to establish business accounts or meet medical licensing requirements for certain products. This indicates that its commercial model differs from a conventional direct-to-consumer supplement business.

The company’s positioning sits at the intersection of pharmaceutical outsourcing, healthcare-provider supply, and specialized product development. Its B2B sales model makes medical practices, provider networks, and other eligible healthcare organizations important customer segments. Research and development partnerships may also be relevant to its business, although the current status and commercial terms of individual partnerships should be confirmed.

For business development, GenoGenix could be a prospect for qualified B2B account research, healthcare-provider prospecting, professional outreach, partnership identification, and sales pipeline support. Marketing and outreach activities should be aligned with pharmaceutical regulations, product-specific requirements, customer eligibility, and the company’s current regulatory status.

Regulatory context is particularly important. The FDA issued an inspectional observations report (Form FDA 483) following an inspection of GenoGenix, LLC from July 14–18, 2025. The report documented observations concerning sterile-drug manufacturing and contamination-control procedures. The FDA states that inspectional observations are not, by themselves, a final agency determination of compliance. Any current assessment of the company’s operations should therefore review subsequent FDA correspondence, company responses, and later regulatory developments rather than treating the inspection report alone as a complete statement of present status.